Patents by Inventor Robert C. Andrews
Robert C. Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9815263Abstract: A method for manufacturing a thin film structural system including a thin film structure includes depositing a reinforcing material in a liquid form in a predefined pattern on a thin film membrane, and transforming the reinforcing material in the predefined pattern to form a reinforcing element connected to the thin film membrane. The reinforcing material may be deposited in a melted form and solidified by cooling, may be transformed by a light or laser induced chemical reaction, or may be deposited and solidified such that the reinforcing element is at least partially embedded in the thin film membrane. The predefined pattern may redistribute loads around a damaged portion of the thin film structure, or define a hinge, a folding line, a stiffening feature. The reinforcing element may be electrically, optically or thermally conductive, to communicate with a device included in the system. The system may be a space structure.Type: GrantFiled: October 14, 2011Date of Patent: November 14, 2017Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASAInventors: Wendell Keith Belvin, David W. Sleight, John W. Connell, Thomas J. Burns, Nancy M. H. Holloway, Frank L. Palmieri, Gary A. Wainwright, Robert C. Andrews, Martin Eckhard Zander
-
Patent number: 9045461Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: March 26, 2014Date of Patent: June 2, 2015Assignee: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Publication number: 20140206660Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Patent number: 8741900Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: February 21, 2013Date of Patent: June 3, 2014Assignee: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Patent number: 8598353Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: GrantFiled: November 19, 2010Date of Patent: December 3, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, David R. Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff J. Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
-
Patent number: 8563742Abstract: Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.Type: GrantFiled: August 25, 2009Date of Patent: October 22, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Robert C. Andrews, Samuel Victory, Suparna Gupta
-
Patent number: 8431575Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: February 15, 2011Date of Patent: April 30, 2013Assignee: TransTech Pharma, Inc.Inventors: Devi R Gohimukkula, David Robert Jones, Ghassan Qabaja, Jeff J Zhu, Jeremy T Cooper, William K Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Suparna Gupta, Anitha Hari, Raju B Gowda, Robert C Andrews
-
Patent number: 8404731Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.Type: GrantFiled: January 11, 2010Date of Patent: March 26, 2013Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
-
Patent number: 8377983Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.Type: GrantFiled: February 10, 2010Date of Patent: February 19, 2013Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
-
Publication number: 20120196906Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.Type: ApplicationFiled: March 6, 2012Publication date: August 2, 2012Applicant: TransTech Pharma, Inc.Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
-
Publication number: 20120177892Abstract: A method for manufacturing a thin film structural system including a thin film structure includes depositing a reinforcing material in a liquid form in a predefined pattern on a thin film membrane, and transforming the reinforcing material in the predefined pattern to form a reinforcing element connected to the thin film membrane. The reinforcing material may be deposited in a melted form and solidified by cooling, may be transformed by a light or laser induced chemical reaction, or may be deposited and solidified such that the reinforcing element is at least partially embedded in the thin film membrane. The predefined pattern may redistribute loads around a damaged portion of the thin film structure, or define a hinge, a folding line, a stiffening feature. The reinforcing element may be electrically, optically or thermally conductive, to communicate with a device included in the system. The system may be a space structure.Type: ApplicationFiled: October 14, 2011Publication date: July 12, 2012Applicant: U.S.A. as represented by the Administrator of the National Aeronautics and Space AdministrationInventors: Wendell Keith Belvin, David W. Sleight, John W. Connell, Thomas J. Burns, Nancy M.H. Holloway, Frank L. Palmieri, Gary A. Wainwright, Robert C. Andrews, Martin Eckhard Zander
-
Publication number: 20120088778Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.Type: ApplicationFiled: October 10, 2011Publication date: April 12, 2012Applicant: TransTech Pharma, Inc.Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi S. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
-
Publication number: 20110230458Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: ApplicationFiled: February 15, 2011Publication date: September 22, 2011Applicant: TransTech Pharma, Inc.Inventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari
-
Patent number: 7944093Abstract: A system according to the present invention including a main utility distribution panel which through corresponding circuit breakers, directly powers facility power line circuits which remain powered continuously, and an ‘off-peak’ utility distribution panel being powered by the main utility distribution panel through a contactor (relay, switch, etc.) controlled by a 24 hour timer, and the ‘off-peak’ utility distribution panel in turn powers facility power line circuits which may be de-energized to provide zero power draw from the main utility distribution panel during a selected time period as provided by the timer, which generally corresponds to periods when the facility is unoccupied and/or the equipment and appliances are turned off.Type: GrantFiled: March 27, 2009Date of Patent: May 17, 2011Inventor: Robert C. Andrews, Jr.
-
Publication number: 20110092553Abstract: The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.Type: ApplicationFiled: November 19, 2010Publication date: April 21, 2011Applicant: TransTech Pharma, Inc.Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
-
Publication number: 20110077399Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.Type: ApplicationFiled: December 1, 2010Publication date: March 31, 2011Applicant: TRANSTECH PHARMA, INC.Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Dharma R. Polisetti
-
Publication number: 20110065713Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: ApplicationFiled: November 19, 2010Publication date: March 17, 2011Applicant: High Point Pharmaceuticals, LLCInventors: Adnan M.M. Mjalli, David Jones, Devi Reddy Gohimmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
-
Patent number: 7893267Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.Type: GrantFiled: March 14, 2006Date of Patent: February 22, 2011Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, David Jones, Devi Reddy Gohimmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
-
Patent number: 7820704Abstract: The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.Type: GrantFiled: April 20, 2005Date of Patent: October 26, 2010Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Bapu R. Gaddam, Ghassan Qabaja, Govindan Subramanian, Jeff Zhu, John Dankwardt, Murty N. Arimilli, Robert C. Andrews, Samuel Victory, Ye E. Tian
-
Patent number: 7820821Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.Type: GrantFiled: February 9, 2007Date of Patent: October 26, 2010Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu